Details for New Drug Application (NDA): 212287
✉ Email this page to a colleague
The generic ingredient in PIPERACILLIN AND TAZOBACTAM is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.
Summary for 212287
| Tradename: | PIPERACILLIN AND TAZOBACTAM |
| Applicant: | Astral |
| Ingredient: | piperacillin sodium; tazobactam sodium |
| Patents: | 0 |
Pharmacology for NDA: 212287
| Mechanism of Action | beta Lactamase Inhibitors |
Suppliers and Packaging for NDA: 212287
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 212287 | ANDA | Xellia Pharmaceuticals USA LLC | 70594-078 | 70594-078-02 | 10 VIAL in 1 CARTON (70594-078-02) / 50 mL in 1 VIAL (70594-078-01) |
| PIPERACILLIN AND TAZOBACTAM | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 212287 | ANDA | Xellia Pharmaceuticals USA LLC | 70594-079 | 70594-079-02 | 10 VIAL in 1 CARTON (70594-079-02) / 100 mL in 1 VIAL (70594-079-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL | ||||
| Approval Date: | Jul 29, 2019 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL | ||||
| Approval Date: | Jul 29, 2019 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | ||||
| Approval Date: | Jul 29, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
